|
Safety and efficacy of once-weekly carfilzomib (K) dosing in frail patients (pts): A subgroup analysis from the phase 3 A.R.R.O.W. study. |
|
|
Honoraria - Amgen; Celgene; Janssen-Cilag; Takeda |
Consulting or Advisory Role - Amgen; Celgene; Janssen-Cilag; Takeda |
|
|
Consulting or Advisory Role - Pharma Marathi |
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Celgene; Janssen; Takeda |
Research Funding - Amgen (Inst); Takeda (Inst) |
|
|
|
Consulting or Advisory Role - Abbvie (Inst); Abbvie (Inst); Adaptive Biotechnologies; Amgen (Inst); Celgene (Inst); Genecentrix; Genentech/Roche (Inst); Janssen Oncology (Inst); Kite, a Gilead company (Inst); Merck (Inst); Oncopeptides; Takeda (Inst) |
Research Funding - Abbvie (Inst); Celgene (Inst); Janssen Oncology (Inst); Kite, a Gilead company (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Roche/Genentech (Inst); Sanofi (Inst); Takeda (Inst) |
|
|
Honoraria - Bristol-Myers Squibb; Celgene |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Celgene |
|
|
|
Stock and Other Ownership Interests - Amgen |
|
|
|
Stock and Other Ownership Interests - Amgen |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; Bristol-Myers Squibb; Celgene; Janssen-Cilag; Takeda |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Janssen-Cilag; Takeda |